Credit Suisse Downgrades Pfizer to Neutral, Lowers Price Target to $40
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Trung Huynh has downgraded Pfizer from Outperform to Neutral and lowered the price target from $47 to $40.
June 29, 2023 | 8:58 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer has been downgraded from Outperform to Neutral by Credit Suisse, with a lowered price target from $47 to $40.
The downgrade from Outperform to Neutral indicates a less optimistic outlook for Pfizer's stock performance. The lowered price target from $47 to $40 suggests that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100